SAA1 and COVID-19: Due to the large amounts of SAA in the serum of COVID-19 patients, attempts to outcompete SAA and prevent its binding to platelets or reduce platelet adhesion using an anti-SAA antibody or SAA-derived peptides were unsuccessful.